Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- AbbVie Japan Files Rinvoq 30 mg Regimen for Age 12-Plus Atopic Dermatitis Patients
November 16, 2023
- Change in Dynamics? Suzuken Emerges as No. 2 among Big 4 Japan Wholesalers
November 15, 2023
- Kao, NANO MRNA to Initiate Joint Research for mRNA Drug Discovery
November 15, 2023
- iPark Institute Inks Collaboration Pact with South Korean Government
November 14, 2023
- Japan’s First Stelara Biosimilar to Skip November Listing on Risk of Import Delays: Fuji Pharma
November 14, 2023
- Taisho Hits “Reset” Button for Pharma Biz with 600-Plus Job Cuts
November 14, 2023
- Ajinomoto to Acquire US Gene Therapy CDMO for US$554 Million
November 14, 2023
- UCB Seeks Hidradenitis Suppurativa Nod for Bimzelx in Japan
November 13, 2023
- Otsuka Files NDA for Lupus Nephritis Drug in Japan
November 13, 2023
- Takeda Scores 1st US Nod for Ultra-Rare Blood Clotting Disorder
November 13, 2023
- Daiichi Sankyo’s FLT3 Inhibitor Gets EU Approval for 1st Line AML
November 10, 2023
- Takeda Gets US Clearance for Hutchmed’s Colorectal Cancer Drug
November 10, 2023
- Middle East Unrest Threatens Supply of Kaken’s Burn Eschar Remover
November 9, 2023
- Mitsubishi Licenses Neuropsychiatric Drug to Dutch Startup Kynexis
November 9, 2023
- Japan Ethical Drug Sales Up 6.8% in September: Crecon
November 9, 2023
- Japan OB/GYN Market Projected at 100 Billion Yen in FY2026: Fuji Keizai
November 9, 2023
- CSL Launches Original Home Delivery Service for Hizentra
November 8, 2023
- Upsher-Smith’s Livalo Generic Hits US Market: Sawai
November 8, 2023
- Eisai CEO Confident of Achieving Leqembi Sales Goal of 10 Billion Yen in FY2023
November 8, 2023
- Keytruda Snares Title in Japan Sales Ranking in October: Encise
November 8, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…